Back to compounds

COMPOUND PROFILE / PROTEINS & BIOLOGICS

Maridebart Cafraglutide / MariTide.

Research draft

Maridebart cafraglutide, also called MariTide or AMG 133, is a peptide-antibody conjugate investigated for metabolic disease.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Maridebart cafraglutide, also called MariTide or AMG 133, is a peptide-antibody conjugate investigated for metabolic disease.

CLASSIFICATIONProteins & biologics
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It combines GLP-1 receptor agonism with GIP receptor antagonism.

Human research

Registered and reported clinical development must be evaluated by exact formulation and trial; this mechanism differs from GIP agonists.

Preclinical & other research

Preclinical work explored receptor combination and prolonged exposure.

Safety & unknowns

Gastrointestinal tolerability and effects of long exposure need clinical assessment.

Regulatory status

Investigational in reviewed sources; do not infer approval or equivalence to tirzepatide.

Reported use & evidence

Research profile draft

The supplied Maridebart Cafraglutide / MariTide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Follow the cited records and registered research. Profiles remain research drafts.

Explore more compounds